Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors

Antonio Jimeno, Glen J. Weiss, Wilson H. Miller, Scott Gettinger, Bernard J C Eigl, Anne Lynne S Chang, Joi Dunbar, Shannon Devens, Kerrie Faia, Georgios Skliris, Jeff Kutok, Karl D. Lewis, Raoul Tibes, William H. Sharfman, Robert W. Ross, Charles M. Rudin

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Purpose: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). Experimental Design: Patients with solid tumors refractory to standard therapy were given IPI-926 once daily (QD) by mouth in 28-day cycles. The starting dose was 20 mg, and an accelerated titration schedule was used until standard 3 + 3 dose-escalation cohorts were implemented. Pharmacokinetics were evaluated on day -7 and day 22 of cycle 1. Results: Ninety-four patients (32F, 62M; ages, 39-87) received doses ranging from 20 to 210 mg QD. Dose levels up to and including 160 mg administered QD were well tolerated. Toxicities consisted of reversible elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin, fatigue, nausea, alopecia, and muscle spasms. IPI-926 was not associated with hematologic toxicity. IPI-926 pharmacokinetics were characterized by a slow absorption (Tmax = 2-8 hours) and a terminal half-life (t1/2) between 20 and 40 hours, supporting QD dosing. Of those HhP inhibitor-naïve patients with basal cell carcinoma (BCC) who received more than one dose of IPI-926 and had a follow-up clinical or Response Evaluation Criteria in Solid Tumors (RECIST) assessment, nearly a third (8 of 28 patients) showed a response to IPI-926 at doses ≥130 mg. Conclusions: IPI-926 was well tolerated up to 160 mg QD within 28-day cycles, which was established as the recommended phase II dose and schedule for this agent. Single-agent activity of IPI-926 was observed in HhP inhibitor-naïve patients with BCC.

Original languageEnglish (US)
Pages (from-to)2766-2774
Number of pages9
JournalClinical Cancer Research
Volume19
Issue number10
DOIs
StatePublished - May 15 2013
Externally publishedYes

Fingerprint

Neoplasms
Pharmacokinetics
Basal Cell Carcinoma
Appointments and Schedules
IPI-926
Alopecia
Spasm
Aspartate Aminotransferases
Alanine Transaminase
Bilirubin
Nausea
Fatigue
Half-Life
Mouth
Research Design
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Jimeno, A., Weiss, G. J., Miller, W. H., Gettinger, S., Eigl, B. J. C., Chang, A. L. S., ... Rudin, C. M. (2013). Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clinical Cancer Research, 19(10), 2766-2774. https://doi.org/10.1158/1078-0432.CCR-12-3654

Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. / Jimeno, Antonio; Weiss, Glen J.; Miller, Wilson H.; Gettinger, Scott; Eigl, Bernard J C; Chang, Anne Lynne S; Dunbar, Joi; Devens, Shannon; Faia, Kerrie; Skliris, Georgios; Kutok, Jeff; Lewis, Karl D.; Tibes, Raoul; Sharfman, William H.; Ross, Robert W.; Rudin, Charles M.

In: Clinical Cancer Research, Vol. 19, No. 10, 15.05.2013, p. 2766-2774.

Research output: Contribution to journalArticle

Jimeno, A, Weiss, GJ, Miller, WH, Gettinger, S, Eigl, BJC, Chang, ALS, Dunbar, J, Devens, S, Faia, K, Skliris, G, Kutok, J, Lewis, KD, Tibes, R, Sharfman, WH, Ross, RW & Rudin, CM 2013, 'Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors', Clinical Cancer Research, vol. 19, no. 10, pp. 2766-2774. https://doi.org/10.1158/1078-0432.CCR-12-3654
Jimeno, Antonio ; Weiss, Glen J. ; Miller, Wilson H. ; Gettinger, Scott ; Eigl, Bernard J C ; Chang, Anne Lynne S ; Dunbar, Joi ; Devens, Shannon ; Faia, Kerrie ; Skliris, Georgios ; Kutok, Jeff ; Lewis, Karl D. ; Tibes, Raoul ; Sharfman, William H. ; Ross, Robert W. ; Rudin, Charles M. / Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 10. pp. 2766-2774.
@article{c9f043a8d98c499484402ef2f9614ed8,
title = "Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors",
abstract = "Purpose: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). Experimental Design: Patients with solid tumors refractory to standard therapy were given IPI-926 once daily (QD) by mouth in 28-day cycles. The starting dose was 20 mg, and an accelerated titration schedule was used until standard 3 + 3 dose-escalation cohorts were implemented. Pharmacokinetics were evaluated on day -7 and day 22 of cycle 1. Results: Ninety-four patients (32F, 62M; ages, 39-87) received doses ranging from 20 to 210 mg QD. Dose levels up to and including 160 mg administered QD were well tolerated. Toxicities consisted of reversible elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin, fatigue, nausea, alopecia, and muscle spasms. IPI-926 was not associated with hematologic toxicity. IPI-926 pharmacokinetics were characterized by a slow absorption (Tmax = 2-8 hours) and a terminal half-life (t1/2) between 20 and 40 hours, supporting QD dosing. Of those HhP inhibitor-na{\"i}ve patients with basal cell carcinoma (BCC) who received more than one dose of IPI-926 and had a follow-up clinical or Response Evaluation Criteria in Solid Tumors (RECIST) assessment, nearly a third (8 of 28 patients) showed a response to IPI-926 at doses ≥130 mg. Conclusions: IPI-926 was well tolerated up to 160 mg QD within 28-day cycles, which was established as the recommended phase II dose and schedule for this agent. Single-agent activity of IPI-926 was observed in HhP inhibitor-na{\"i}ve patients with BCC.",
author = "Antonio Jimeno and Weiss, {Glen J.} and Miller, {Wilson H.} and Scott Gettinger and Eigl, {Bernard J C} and Chang, {Anne Lynne S} and Joi Dunbar and Shannon Devens and Kerrie Faia and Georgios Skliris and Jeff Kutok and Lewis, {Karl D.} and Raoul Tibes and Sharfman, {William H.} and Ross, {Robert W.} and Rudin, {Charles M.}",
year = "2013",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-12-3654",
language = "English (US)",
volume = "19",
pages = "2766--2774",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors

AU - Jimeno, Antonio

AU - Weiss, Glen J.

AU - Miller, Wilson H.

AU - Gettinger, Scott

AU - Eigl, Bernard J C

AU - Chang, Anne Lynne S

AU - Dunbar, Joi

AU - Devens, Shannon

AU - Faia, Kerrie

AU - Skliris, Georgios

AU - Kutok, Jeff

AU - Lewis, Karl D.

AU - Tibes, Raoul

AU - Sharfman, William H.

AU - Ross, Robert W.

AU - Rudin, Charles M.

PY - 2013/5/15

Y1 - 2013/5/15

N2 - Purpose: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). Experimental Design: Patients with solid tumors refractory to standard therapy were given IPI-926 once daily (QD) by mouth in 28-day cycles. The starting dose was 20 mg, and an accelerated titration schedule was used until standard 3 + 3 dose-escalation cohorts were implemented. Pharmacokinetics were evaluated on day -7 and day 22 of cycle 1. Results: Ninety-four patients (32F, 62M; ages, 39-87) received doses ranging from 20 to 210 mg QD. Dose levels up to and including 160 mg administered QD were well tolerated. Toxicities consisted of reversible elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin, fatigue, nausea, alopecia, and muscle spasms. IPI-926 was not associated with hematologic toxicity. IPI-926 pharmacokinetics were characterized by a slow absorption (Tmax = 2-8 hours) and a terminal half-life (t1/2) between 20 and 40 hours, supporting QD dosing. Of those HhP inhibitor-naïve patients with basal cell carcinoma (BCC) who received more than one dose of IPI-926 and had a follow-up clinical or Response Evaluation Criteria in Solid Tumors (RECIST) assessment, nearly a third (8 of 28 patients) showed a response to IPI-926 at doses ≥130 mg. Conclusions: IPI-926 was well tolerated up to 160 mg QD within 28-day cycles, which was established as the recommended phase II dose and schedule for this agent. Single-agent activity of IPI-926 was observed in HhP inhibitor-naïve patients with BCC.

AB - Purpose: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). Experimental Design: Patients with solid tumors refractory to standard therapy were given IPI-926 once daily (QD) by mouth in 28-day cycles. The starting dose was 20 mg, and an accelerated titration schedule was used until standard 3 + 3 dose-escalation cohorts were implemented. Pharmacokinetics were evaluated on day -7 and day 22 of cycle 1. Results: Ninety-four patients (32F, 62M; ages, 39-87) received doses ranging from 20 to 210 mg QD. Dose levels up to and including 160 mg administered QD were well tolerated. Toxicities consisted of reversible elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin, fatigue, nausea, alopecia, and muscle spasms. IPI-926 was not associated with hematologic toxicity. IPI-926 pharmacokinetics were characterized by a slow absorption (Tmax = 2-8 hours) and a terminal half-life (t1/2) between 20 and 40 hours, supporting QD dosing. Of those HhP inhibitor-naïve patients with basal cell carcinoma (BCC) who received more than one dose of IPI-926 and had a follow-up clinical or Response Evaluation Criteria in Solid Tumors (RECIST) assessment, nearly a third (8 of 28 patients) showed a response to IPI-926 at doses ≥130 mg. Conclusions: IPI-926 was well tolerated up to 160 mg QD within 28-day cycles, which was established as the recommended phase II dose and schedule for this agent. Single-agent activity of IPI-926 was observed in HhP inhibitor-naïve patients with BCC.

UR - http://www.scopus.com/inward/record.url?scp=84878037234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878037234&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-3654

DO - 10.1158/1078-0432.CCR-12-3654

M3 - Article

VL - 19

SP - 2766

EP - 2774

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -